keyword
MENU ▼
Read by QxMD icon Read
search

Nivolumab lung

keyword
https://www.readbyqxmd.com/read/29133768/severe-pneumonitis-after-nivolumab-treatment-accompanied-by-acute-pulmonary-embolism-in-a-patient-with-lung-adenocarcinoma
#1
Ji-Ping Liao, Li-Gong Nie, Cheng-Li Que, Xiang-Dong Mu
No abstract text is available yet for this article.
November 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/29133121/analysis-of-early-death-in-japanese-patients-with-advanced-non-small-cell-lung-cancer-treated-with-nivolumab
#2
Takako Inoue, Motohiro Tamiya, Akihiro Tamiya, Kenji Nakahama, Yoshihiko Taniguchi, Takayuki Shiroyama, Shin-Ichi Isa, Kazumi Nishino, Toru Kumagai, Kei Kunimasa, Madoka Kimura, Hidekazu Suzuki, Tomonori Hirashima, Shinji Atagi, Fumio Imamura
BACKGROUND: The increased risk for early death owing to anti-programmed cell death 1 inhibitors is a major disadvantage that requires special management. We evaluated the frequency, causes, and risk factors of early death during nivolumab treatment for non-small cell lung cancer (NSCLC) in a Japanese clinical setting. PATIENTS AND METHODS: The medical records of patients with NSCLC who started receiving nivolumab between December 17, 2015 and July 31, 2016 in 3 Japanese institutes were collected...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29129758/impact-of-nivolumab-versus-docetaxel-on-health-related-quality-of-life-and-symptoms-in-patients-with-advanced-squamous-non-small-cell-lung-cancer-results-from-the-checkmate-017-study
#3
Martin Reck, Fiona Taylor, John R Penrod, Michael DeRosa, Laura Morrissey, Homa Dastani, Lucinda Orsini, Richard J Gralla
INTRODUCTION: In the phase III CheckMate 017 study, nivolumab prolonged overall survival versus docetaxel in previously treated patients with advanced squamous non-small cell lung cancer (NSCLC). Study objectives included health-related quality of life (HRQoL) and symptom assessments. METHODS: Patients serially completed Lung Cancer Symptom Scale (LCSS) and European Quality of Life Five Dimensions (EQ-5D) questionnaires. The LCSS average symptom burden index (ASBI; mean score for six lung cancer-specific symptoms; range, 0-100), LCSS 3-item global index, EQ-5D utility index, and EQ-5D visual analog scale scores were analyzed...
November 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29124007/immunotherapy-shock-with-vitiligo-due-to-nivolumab-administration-as-third-line-therapy-in-lung-adenocarcinoma
#4
Paul Zarogoulidis, Haidong Huang, Theodora Tsiouda, Chrysa Sardeli, Georgia Trakada, Lemonia Veletza, Anastasios Kallianos, Christoforos Kosmidis, Aggeliki Rapti, Liana Papaemmanouil, Dimitrios Hatzibougias, Dimitrios Drougas, Chong Bai, Wolfgang Hohenforst-Schmidt
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/29119852/platelet-related-indices-in-patients-with-lung-cancer-with-nivolumab
#5
Shosaku Nomura, Takashi Yokoi, Takayasu Kurata
No abstract text is available yet for this article.
November 9, 2017: Platelets
https://www.readbyqxmd.com/read/29106466/nivolumab-in-hiv-related-non-small-cell-lung-cancer
#6
M Hentrich, K Schipek-Voigt, H Jäger, S Schulz, P Schmid, O Stötzer, P Bojko
No abstract text is available yet for this article.
July 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29102951/potential-risk-factors-for-nivolumab-induced-thyroid-dysfunction
#7
Haruhiko Yamazaki, Hiroyuki Iwasaki, Toshinari Yamashita, Tatsuya Yoshida, Nobuyasu Suganuma, Takashi Yamanaka, Katsuhiko Masudo, Hirotaka Nakayama, Kaori Kohagura, Yasushi Rino, Munetaka Masuda
BACKGROUND: Thyroid dysfunction is occasionally reported after the administration of nivolumab. We report on the incidence of and risk factors for nivolumab-induced thyroid dysfunction in patients with non-small lung cancer. PATIENTS AND METHODS: A total of 82 patients who received nivolumab between January 2016 and December 2016 at the Kanagawa Cancer Center were included. Prior to nivolumab treatment, 72 patients had normal thyroid function. RESULTS: Among the 72 patients with normal thyroid function prior to nivolumab treatment, the incidence of thyroid dysfunction was 19...
November 2017: In Vivo
https://www.readbyqxmd.com/read/29096940/anti-pd1-pdl1-induced-psoriasis
#8
Dimitra Voudouri, Vasiliki Nikolaou, Konstantinos Laschos, Andriani Charpidou, Nikolaos Soupos, Ioanna Triantafyllopoulou, Ioanna Panoutsopoulou, Gerasimos Aravantinos, K Syrigos, A Stratigos
BACKGROUND: Immune checkpoint inhibitors are novel agents approved for the treatment of late-stage malignancies. Despite its important clinical benefits, checkpoint inhibition is associated with a unique spectrum of side effects known as immune-related adverse events. Skin toxicities are the most frequent immune-related adverse events during anti-PD1 blockade therapies. Among them, rare cases of psoriasis exacerbation have been reported. METHODS: We present the clinical characteristics of exacerbated psoriasis in 5 patients under anti-PD1/PDL1 therapy...
October 18, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/29093678/immune-related-adverse-events-associated-with-anti-pd-1-pd-l1-treatment-for-malignancies-a-meta-analysis
#9
Peng-Fei Wang, Yang Chen, Si-Ying Song, Ting-Jian Wang, Wen-Jun Ji, Shou-Wei Li, Ning Liu, Chang-Xiang Yan
Background: Treatment of cancers with programmed cell death protein 1 (PD-1) pathway inhibitors can lead to immune-related adverse events (irAEs), which could be serious and even fetal. Therefore, clinicians should be aware of the characteristics of irAEs associated with the use of such drugs. Methods: The MEDLINE, EMBASE, and Cochrane databases were searched to find potential studies using the following strategies: anti-PD-1/PD-L1 treatment; irAEs; and cancer. R© package Meta was used to pool incidence. Results: Forty-six studies representing 12,808 oncologic patients treated with anti-PD-1/PD-L1 agents were included in the meta-analysis...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29084031/companion-and-complementary-diagnostics-focus-on-pd-l1-expression-assays-for-pd-1-pd-l1-checkpoint-inhibitors-in-nsclc
#10
Maria Hersom, Jan Trøst Jørgensen
Over the last couple of decades, molecular diagnostics have played an increasing role in drug development. Especially within oncology, more and more drugs are being developed together with a predictive biomarker assay using the drug-diagnostic co-development model. Not only do these assays support the development process but also the use of the drugs after regulatory approval as an important treatment decision tool. When these predictive biomarker assays are linked to a specific drug, they are called companion diagnostics...
October 27, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29082855/comparative-efficacy-and-safety-of-second-line-treatments-for-advanced-non-small-cell-lung-cancer-with-wild-type-or-unknown-status-for-epidermal-growth-factor-receptor-a-systematic-review-and-network-meta-analysis
#11
Perrine Créquit, Anna Chaimani, Amélie Yavchitz, Nassima Attiche, Jacques Cadranel, Ludovic Trinquart, Philippe Ravaud
BACKGROUND: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs) on this topic is increasing. Our objective was to assess the comparative effectiveness and tolerability of all second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR by a systematic review and network meta-analysis...
October 30, 2017: BMC Medicine
https://www.readbyqxmd.com/read/29078173/very-early-response-of-circulating-tumour-derived-dna-in-plasma-predicts-efficacy-of-nivolumab-treatment-in-patients-with-non-small-cell-lung-cancer
#12
Yuki Iijima, Yosuke Hirotsu, Kenji Amemiya, Yoshihiko Ooka, Hitoshi Mochizuki, Toshio Oyama, Takahiro Nakagomi, Yoshinori Uchida, Yoichi Kobayashi, Toshiharu Tsutsui, Yumiko Kakizaki, Taichiro Goto, Yoshihiro Miyashita, Masao Omata
INTRODUCTION: Immunotherapy has become a treatment option for lung cancer. The utility of nivolumab as second-line treatment for non-small cell lung cancer has been proven, but predictive biomarkers influencing its efficacy remain unknown. METHODS: This study involved 14 patients who were treated with nivolumab from February 1 to September 30, 2016. The early response of the level of circulating tumour DNA (ctDNA) after starting nivolumab was evaluated to ascertain whether it could predict treatment outcome...
October 24, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29074606/low-pd-1-expression-in-cytotoxic-cd8-tumor-infiltrating-lymphocytes-confers-an-immune-privileged-tissue-microenvironment-in-nsclc-with-a-prognostic-and-predictive-value
#13
Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini, Matteo Goldoni, Francesco Sogni, Giovanna Armani, Costanza Annamaria Lagrasta, Bruno Lorusso, Chiara Maria Mangiaracina, Rocchina Vilella, Caterina Frati, Roberta R Alfieri, Luca Ampollini, Michele Veneziani, Enrico M Silini, Andrea Ardizzoni, Konrad Urbanek, Franco Aversa, Federico Quaini, Marcello Tiseo
The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue immune microenvironments differentially impact on clinical outcome in Non Small Cell Lung Cancer (NSCLC), an extended analysis of PD-L1 and Tumor Infiltrating Lymphocytes (TILs) was performed. Experimental Design Samples from resected adenocarcinoma (ADC 42) and squamous cell carcinoma (SCC 58) and from 26 advanced diseases (13 ADC, 13 SCC) treated with nivolumab were analyzed...
October 26, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29070994/nivolumab-induced-myocarditis-concomitant-with-myasthenia-gravis
#14
Yoko Fukasawa, Kazuya Sasaki, Maika Natsume, Makoto Nakashima, Shuji Ota, Kiyotaka Watanabe, Yoshihisa Takahashi, Fukuo Kondo, Ken Kozuma, Nobuhiko Seki
We report a 69-year-old female patient with advanced lung cancer who developed myocarditis concomitant with myasthenia gravis (MG), also known as "Herzmyasthenie," after 3 cycles of nivolumab administration. Her initial symptoms were general malaise and double vision. However, her myocarditis deteriorated rapidly the following day, necessitating a temporary pacemaker and noninvasive positive pressure ventilation in the intensive care unit. Immunohistochemical examination of a myocardial biopsy suggested an immune response on the basis of HLA associations...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29070993/different-response-to-nivolumab-in-a-patient-with-synchronous-double-primary-carcinomas-of-hypopharyngeal-cancer-and-non-small-cell-lung-cancer
#15
Teppei Yamaguchi, Kazuo Sakurai, Makoto Kuroda, Kazuyoshi Imaizumi, Toyoaki Hida
Nivolumab is a humanized IgG4 and programmed death 1 (PD-1) monoclonal antibody that has demonstrated antitumor efficacy in clinical trials of various malignant tumors including non-small-cell lung cancer and head and neck squamous cell carcinoma (SCC). However, patients with multiple primary malignancies were excluded in clinical trials. Thus, the efficacy of nivolumab in such patients has not been revealed yet. The programmed death ligand 1 (PD-L1) expression level is currently the main predictive biomarker of PD-1 inhibitors in various types of solid tumors and hematological malignancies...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29069302/mechanistic-overview-of-immune-checkpoints-to-support-the-rational-design-of-their-combinations-in-cancer-immunotherapy
#16
A Rotte, J Y Jin, V Lemaire
Checkpoint receptor blockers, known to act by blocking the pathways that inhibit immune cell activation and stimulate immune responses against tumor cells, have been immensely successful in the treatment of cancer. Among several checkpoint receptors of immune cells, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), T-cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin-3 (TIM-3) and lymphocyte activation gene 3 (LAG-3) are the most commonly targeted checkpoints for cancer immunotherapy...
October 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29067858/immune-related-intestinal-pseudo-obstruction-associated-with-nivolumab-treatment-in-a-lung-cancer-patient
#17
Georgios Fragulidis, Eirini Pantiora, Vasiliki Michalaki, Elissaios Kontis, Elias Primetis, Antonios Vezakis, Andreas Polydorou
Immune checkpoint inhibition therapy using targeted monoclonal antibodies is a new therapeutic approach with significant survival benefit for patients with several cancer types. However, their use can be associated with unique immune-related adverse effects as a consequence of impaired self-tolerance due to loss of T-cell inhibition via a nonselective activation of the immune system. Nivolumab is an anti-PD-1 immune checkpoint inhibitor that was recently developed for cancer immunotherapy with remarkable responses in nonsmall cell lung cancer patients...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29067215/nivolumab-induced-hypothyroidism-and-selective-pituitary-insufficiency-in-a-patient-with-lung-adenocarcinoma-a-case-report-and-review-of-the-literature
#18
Myrto Kastrisiou, Fereniki-Lida Kostadima, Aristides Kefas, George Zarkavelis, Nikos Kapodistrias, Evangelos Ntouvelis, Dimitrios Petrakis, Alexandra Papadaki, Amalia Vassou, George Pentheroudakis
Immune checkpoint blockade including programmed cell death 1 pathway inhibition with agents such as nivolumab is gaining ground in a wide array of malignancies, so far demonstrating significantly improved survival rates even in metastatic, often multiply pretreated settings. Although targeted in nature and generally well-tolerated compared with conventional anticancer treatments, these agents are often linked to a newly emerged group of adverse reactions, referred to as immune-related adverse events, which can also affect endocrine organs...
2017: ESMO Open
https://www.readbyqxmd.com/read/29066905/a-rare-case-of-lung-carcinoma-acquires-multidrug-resistant-klebsiella-pneumoniae-pneumonia-radiologically-mimicking-metastasis-caused-by-nivolumab-therapy-associated-neutropenia
#19
Chao Liu, Ling Ding, Ye-Han Zhu, Cheng Chen
Nosocomial infections by Klebsiella pneumoniae, especially those due to multidrug-resistant strains, are being increasingly detected. In this report, we present the case of a 63-year-old man with lung squamous carcinoma who received nivolumab therapy due to failure of first-line chemotherapy. This report also demonstrates an association of nivolumab therapy and neutropenia, and supports the use of a combination of tigecycline and meropenem in managing hospitalization-acquired pneumonia caused by multidrug-resistant K...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29063735/remarkable-response-of-nivolumab-refractory-lung-cancer-to-salvage-chemotherapy
#20
Daiki Ogawara, Hiroshi Soda, Keisuke Iwasaki, Takayuki Suyama, Hirokazu Taniguchi, Yuichi Fukuda, Hiroshi Mukae
Promising outcomes of salvage chemotherapy after nivolumab therapy have been reported; however, little is known about the detailed clinical and immunologic features in lung cancer patients in whom nivolumab is unsuccessful. We report two cases of nivolumab-refractory lung cancer, in which chemotherapy resulted in rapid regression of the lung cancer. Upon initial diagnosis, the biopsy specimens showed PD-ligand 1 (PD-L1)-expressing cancer cells, accompanied by tumor-infiltrating lymphocytes with a favorable CD8/CD4 ratio...
October 24, 2017: Thoracic Cancer
keyword
keyword
107280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"